Down-regulation of DcR2 sensitizes androgen-dependent prostate cancer LNCaP cells to TRAIL-induced apoptosis

Cancer Cell International

Volumn 11, Issue , 2011, Pages

  Vindrieux, David ^a   Réveiller, Marie ^b   Chantepie, Jacqueline ^c   Yakoub, Sadok ^d   Deschildre, Catherine ^c   Ruffion, Alain ^e   Devonec, Marian ^e   Benahmed, Mohamed ^c   Grataroli, Renée ^f  

^a CENTRE LÉON BÉRARD   (France)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c INSERM   (France)

^d INRA and University of Auvergne   (France)

^e CENTRE HOSPITALIER LYON SUD   (France)

^f University Lyon i   (France)

Author keywords

Androgen; Apoptosis; DcR2; Prostate cancer; Trail

Indexed keywords

CYTOKINE RECEPTOR; DEATH RECEPTOR 5; DECOY RECEPTOR 2; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL STRAIN LNCAP; CONCENTRATION (PARAMETERS); DOWN REGULATION; GENE SILENCING; HUMAN; HUMAN CELL; PROSTATE CANCER; PROTEIN EXPRESSION;

EID: 82455168244     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-11-42     Document Type: Article

References (47)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA: A Cancer J Clin 2008, 58:71-96.
2. Guseva NV, Taghiyev AF, Rokhlin OW, Cohen MB. Death receptor-induced cell death in prostate cancer. J Cell Biochem 2004, 91:70-99. 10.1002/jcb.10707, 14689583.
3. Zornig M, Hueber AO, Baum W, Evan G. Apoptosis regulators and their role in tumorigenesis. Biochem Biophys Acta 2001, 1551:F1-F37.
4. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002, 2:420-430. 10.1038/nrc821, 12189384.
5. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA, Goodwin RG. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995, 3:673-682. 10.1016/1074-7613(95)90057-8, 8777713.
6. Pitti RM, Masters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996, 271:12687-12690. 10.1074/jbc.271.22.12687, 8663110.
7. Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 1999, 11:255-260. 10.1016/S0955-0674(99)80034-9, 10209153.
8. Zhang X, Jin TG, Yang H, DeWolf WC, Khosravi-Far R, Olumi AF. Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer. Cancer Research 2004, 64:7086-7091. 10.1158/0008-5472.CAN-04-1498, 15466204.
9. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z, Schwall RH. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999, 104:155-62. 10.1172/JCI6926, 408479, 10411544.
10. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC, Lynch DH. Tumoricidal activity of tumor necrosis factor-related apoptosis -inducing ligand in vivo. Nat Med 1999, 5:157-63. 10.1038/5517, 9930862.
11. Schneider P, Thome M, Burns K, Bodmer JL, Hofmann K, Kataoka T, Holler N, Tschopp J. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-κB. Immunity 1997, 7:831-836. 10.1016/S1074-7613(00)80401-X, 9430228.
12. Pan G, Ni J, Wei YF, Yu GL, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997, 277:815-818. 10.1126/science.277.5327.815, 9242610.
13. Degli-Esposti MA, Smolak PJ, Walczak H, Waugh J, Huang CP, DuBose RF, Goodwin RG, Smith CA. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med 1997, 186:1165-1170. 10.1084/jem.186.7.1165, 2199077, 9314565.
14. Sheridan JP, Masters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P, Ashkenazi A. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997, 277:818-821. 10.1126/science.277.5327.818, 9242611.
15. Masters SA, Sheridan JP, Pitti RM, Huang A, Skubatch M, Baldwin D, Yuan J, Gurney A, Goddard AD, Godowski P, Ashkenazi A. A novel receptor for Apo2L/TRAIL countains a truncated death domain. Curr Biol 1997, 7:1003-1006. 10.1016/S0960-9822(06)00422-2, 9382840.
16. Pan G, Ni J, Yu GL, Wei YF, Dixit VM. TRUNDD: a new member of the TRAIL receptor family that antagonizes TRAIL signaling. FEBS Lett 1998, 424:41-45. 10.1016/S0014-5793(98)00135-5, 9537512.
17. Clancy L, Mruk K, Archer K, Woelfel M, Mongkolsapaya J, Screaton G, Lenardo MJ, Chan FK. Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis. Proc. Natl. Acad. Sci. USA 2005, 102:18099-18104. 10.1073/pnas.0507329102, 1312398, 16319225.
18. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, Dodds RA, James IE, Rosenberg M, Lee JC, Young PR. Osteoprotegerin Is a Receptor For the Cytotoxic Ligand TRAIL. J Biol Chem 1998, 273:14363-14367. 10.1074/jbc.273.23.14363, 9603945.
19. Riccioni R, Pasquini L, Mariani G, Saulle E, Rossini A, Diverio D, Pelosi E, Vitale A, Chierichini A, Cedrone M, Foa R, Lo Coco F, Peschle C, Testa U. TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL. Haematologica 2005, 90:612-624.
20. Taplin ME, Ho SM. The endocrinology of prostate cancer. J Clin Endocr Metab 2001, 86:3467-3477. 10.1210/jc.86.8.3467, 11502765.
21. Isaacs JT, Lundmo PI, Berges R, Martikainen P, Kyprianou N, English HF. Androgen regulation of programmed death of normal and malignant prostatic cells. J Androl 1992, 13:457-464.
22. Westin P, Stattin P, Damber JE, Bergh A. Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors. Am J Pathol 1995, 146:1368-1375. 1870920, 7778676.
23. Banerjee PP, Banerjee S, Tilly KI, Tilly JL, Brown TR, Zirkin BR. Lobe-specific apoptotic cell death in rat prostate after androgen ablation by castration. Endocrinology 1995, 136:4368-4376. 10.1210/en.136.10.4368, 7664656.
24. Omezzine A, Mauduit C, Tabone E, Nabli N, Bouslama A, Benahmed M. Caspase-3 and -6 expression and activation are targeted by hormone action in the rat ventral prostate during the apoptotic cell death process. Biol Reprod 2003, 69:752-760. 10.1095/biolreprod.102.012435, 12724284.
25. Rokhlin OW, Bishop GA, Hostager BS, Waldschmidt TJ, Sidorenko SP, Pavloff N, Kiefer MC, Umansky SR, Glover RA, Cohen MB. Fas-mediated apoptosis in human prostatic carcinoma cell lines. Cancer Res 1997, 57:1758-1768.
26. De la Taille A, Chen MW, Shabeigh A, Bagiella E, Kiss A, Buttyan R. Fas antigen/CD-95 upregulation and activation during castration-induced regression of the rat ventral prostate gland. Prostate 1999, 40:89-96. 10.1002/(SICI)1097-0045(19990701)40:2<89::AID-PROS4>3.0.CO;2-E, 10386469.
27. Woolveridge I, Taylor MF, Wu FC, Morris ID. Apoptosis and related genes in the rat ventral prostate following androgen ablation in response to ethane dimethanesulfonate. Prostate 1998, 36:23-30.
28. Vindrieux D, Réveiller M, Florin A, Blanchard C, Ruffion A, Devonec M, Benahmed M, Grataroli R. TNF-α Related Apoptosis-Inducing Ligand Decoy Receptor DcR2 is Targeted by Androgen Action in the Rat Ventral Prostate. Journal of Cellular Physiology 2006, 206:709-717. 10.1002/jcp.20520, 16245307.
29. Grataroli R, Vindrieux D, Gougeon A, Benahmed M. Expression of Tumor Necrosis Factor-alpha-Related Apoptosis-Inducing Ligand and Its Receptors in Rat Testis During Development. Biol Reprod 2002, 66:1707-15. 10.1095/biolreprod66.6.1707, 12021051.
30. Bigler D, Gulding KM, Dann R, Sheabar FZ, Conaway MR, Theodorescu D. Gene profiling and promoter reporter assays: novel tools for comparing the biological effects of botanical extracts on human prostate cancer cells and understanding their mechanisms of action. Oncogene 2003, 22:1261-1272. 10.1038/sj.onc.1206242, 12606954.
31. Kalach JJ, Joly-Pharaboz MO, Chantepie J, Nicolas B, Descotes F, Mauduit C, Benahmed M, André J. Divergent biological effects of estradiol and diethylstilbestrol in the prostate cancer cell line MOP. J Steroid Biochem Mol Biol 2005, 96:119-29. 10.1016/j.jsbmb.2005.02.012, 15950459.
32. Rokhlin OW, Taghiyev AF, Guseva NV, Glover RA, Syrbu SI, Cohen MB. TRAIL-DISC formation is androgen-dependent in the human prostatic carcinoma cell line LNCaP. Cancer Biol Ther 2002, 1:631-637.
33. Rokhlin OW, Guseva NV, Tagiyev AF, Glover RA, Cohen MB. Caspase-8 activation is necessary but not sufficient for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in the prostatic carcinoma cell line LNCaP. Prostate 2002, 52(1):1-11. 10.1002/pros.10074, 11992615.
34. Bucur O, Ray S, Bucur MC, Almasan A. APO2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in prostate cancer therapy. Frontiers in Bioscience 2006, 11:1549-1568. 10.2741/1903, 16368536.
35. Rokhlin OW, Taghiyev AF, Guseva NV, Glover RA, Chumakov PM, Kravchenko JE, Cohen MB. Androgen regulates apoptosis induced by TNFR family ligands via multiple signaling pathways in LNCaP. Oncogene 2005, 45:6773-6784.
36. Belyanskaya LL, Marti TM, Hopkins-Donaldson S, Kurtz S, Felley-Bosco E, Stahel RA. Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin. Mol Cancer 2007, 6(1):66. 10.1186/1476-4598-6-66, 2134932, 17953743.
37. MacFarlane M, Kohlhaas SL, Sutcliffe MJ, Dyer MJ, Cohen GM. TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies. Cancer Res 2005, 65:11265-11270. 10.1158/0008-5472.CAN-05-2801, 16357130.
38. Amantana A, London CA, Iversen PL, Devi GR. X-linked inhibitor of apoptosis protein inhibition induces apoptosis and enhances chemotherapy sensitivity in human prostate cancer cells. Mol Cancer Ther 2004, 3:699-707.
39. Chawla-Sarkar M, Bae SL, Reu FJ, Jacobs BS, Lindner DJ, Borden EC. Downregulation of Bcl-2, FLIP or IAPS (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death and Differentiation 2004, 11:915-923. 10.1038/sj.cdd.4401416, 15118763.
40. Sung B, Park B, Yadav VR, Aggarwal BB. Celastrol, a triterpene, enhances TRAIL-induced apoptosis through the down-regulation of cell survival proteins an up-regulation of death receptors. J Biol Chem 2010, 285:11498-11507. 10.1074/jbc.M109.090209, 2857028, 20154087.
41. Hesry V, Piquet-Pellorce C, Travert M, Donaghy L, Jégou B, Patard JJ, Guillaudeux T. Sensitivity of prostate cells to TRAIL-induced apoptosis increase with tumor progression: DR5 and caspase 8 are key players. The Prostate 2006, 66:987-95. 10.1002/pros.20421, 16541419.
42. Munshi A, McDonnell TJ, Meyn RE. Chemotherapeutic agents enhance TRAIL-induced apoptosis in prostate cancer cells. Cancer Chemother Pharmacol 2002, 50:46-52. 10.1007/s00280-002-0465-z, 12111111.
43. Sanlioglu AD, Karacay B, Koksal IT, Griffith TS, Sanlioglu S. DcR2 (TRAIL-R4) siRNA and adenovirus delivery of TRAIL (Ad5hTRAIL) break down in vitro tumorigenic potential of prostate carcinoma cells. Cancer Gene Ther 2007, 14:976-984. 10.1038/sj.cgt.7701087, 17853923.
44. Niu Y, Chang TM, Yeh S, Ma WL, Wang YZ, Chang C. Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails. Oncogene 2010, 29:3593-3604. 10.1038/onc.2010.121, 20440270.
45. Devi GR. XIAP as a target for therapeutic apoptosis in prostate cancer. Drug News Perspect 2004, 17:127-134. 10.1358/dnp.2004.17.2.829046, 15098067.
46. Vindrieux D, Devonec M, Benahmed M, Grataroli R. Identification of tumor necrosis factor-alpha-related apoptosis-inducing ligand (TRAIL) and its receptors in adult rat ventral prostate. Mol Cell Endocrinol 2002, 198:115-121. 10.1016/S0303-7207(02)00407-0, 12573821.
47. Shi J, Zheng D, Lui Y, Sham MH, Tam P, Farzaneh F, Xu R. Overexpression of soluble TRAIL induces apoptosis in human lung adenocarcinoma and inhibits growth of tumor xenografts in nude mice. Cancer Research 2005, 65:1687-1692. 10.1158/0008-5472.CAN-04-2749, 15753363.